Navigation Links
Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations
Date:10/28/2010

PLEASANTON, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said revenues from continuing operations in the third quarter of 2010 increased 40 percent versus the third quarter of 2009.

Results from continuing operations for both the third quarter and first nine months of 2010 and 2009 exclude contributions from the company's International Technidyne Corporation (ITC) Division. In the second quarter of 2010 Thoratec disclosed that its board of directors expects to sell ITC within the next twelve months; therefore, ITC is classified as held for sale and its results are accounted for as a discontinued operation.

For the quarter ended October 2, 2010, revenues were $91.0 million, compared with revenues of $65.1 million in the third quarter of 2009. Net income on a GAAP basis in the third quarter of 2010 was $15.5 million, or $0.26 per diluted share, versus GAAP net income of $11.8 million, or $0.20 per diluted share, in the third quarter of 2009. Non-GAAP net income, which is described later in this press release, was $20.8 million, or $0.32 per diluted share, in the third quarter of 2010, versus non-GAAP net income of $13.3 million, or $0.21 per diluted share, in the third quarter a year ago.

For the first nine months of fiscal 2010, revenues were $285.3 million, an increase of 43 percent over revenues of $198.9 million in the same period a year ago. On a GAAP basis, Thoratec reported net income of $46.4 million, or $0.78 per diluted share, for the first nine months of 2010, versus net income of $20.8 million, or $0.36 per diluted share, in the same period a year ago. Non-GAAP net income in the first nine months of 2010 was $61.7 million, or $0.95 per diluted share, compared with non-GAAP net income of $38.4 million, or $0.61 per diluted share, in the first nine months of 2009.

"The company's results for the third quarter and year-to-date 2010 reflect our success at delivering solid financial results while we continue to execute on our market and product development strategies designed to generate sustained growth for Thoratec over the long term," noted Gary F. Burbach, president and chief executive officer of Thoratec.

"Our top line performance was driven by the continued worldwide adoption of the HeartMate II® LVAS (Left Ventricular Assist System) for Bridge-to-Transplantation (BTT) and Destination Therapy (DT). At the same time, we continued to achieve solid operating leverage as reflected by our earnings performance."

The company indicated that it ended the quarter with 242 HeartMate II centers globally, an increase of 31 centers through the first nine months of 2010, with 181 centers worldwide now utilizing its new HeartMate peripherals, which are providing important quality of life benefits to patients and generating incremental revenue growth.

"Helping to drive our near-term financial performance and market leadership position for the future are investments in our field organization and market development programs that are generating referral activity among cardiologists, while providing centers support in areas including reimbursement and clinical best practices," Burbach said.

Burbach noted that the FDA has approved a label change for the HeartMate II incorporating the data from the company's BTT post-approval study that showed survival of 90 percent at six months and 85 percent at one year. "The outcomes from this study also reflected continued improvements in several important adverse event categories among HeartMate II patients, including zero device replacements and lower reported rates of bleeding, stroke and right heart failure," he commented.

"In addition, we continue to see the release of favorable HeartMate II data in key scientific meetings and publications and are looking forward to a number of important HeartMate II data presentations at next month's Scientific Sessions of the American Heart Association meeting—including outcomes from DT Continued Access Protocol patients, updated cost effectiveness analysis and outcomes for New York Heart Association Class IIIB patients," he added.

FINANCIAL HIGHLIGHTS FROM CONTINUING OPERATIONS

Thoratec reported revenues of $91.0 million in the third quarter of 2010 versus revenues of $65.1 million in the third quarter of 2009.  For the first nine months of 2010, revenues were $285.3 million versus $198.9 million in the first nine months of 2009.  For the third quarter of 2010, revenues in North America were $78.5 million versus $54.3 million in the third quarter a year ago, while international revenues were $12.5 million compared to $10.8 million a year ago. For the third quarter of 2010, foreign exchange rate fluctuations had a $1.1 million unfavorable impact on revenues compared to the same period in 2009. For the first nine months of 2010, revenues in North America were $244.3 million compared to $166.5 million a year ago, while international revenues were $41.0 million compared to $32.4 million in the first nine months of 2009. For the first nine months of 2010, foreign exchange rate fluctuations had a $310,000 unfavorable impact on revenues compared to the same period in 2009.

GAAP gross margin for the third quarter of 2010 was 68.5 percent versus 69.3 percent a year ago. Non-GAAP gross margin, which is described later in this press release, was 68.9 percent versus 69.7 percent in the same period a year ago. The decrease in gross margin reflects unfavorable foreign exchange rates, pump to non-pump mix and increased warranty costs. These factors were offset in part by HeartMate II volume and the continued roll-out of our HeartMate external peripherals.

Operating expenses on a GAAP basis in the third quarter of 2010 were $35.9 million, versus $31.2 million a year ago. On a non-GAAP basis, operating expenses in the third quarter of 2010 were $30.8 million versus $25.7 million in the third quarter of 2009. Operating expenses on a non-GAAP basis are described later in this press release. The year-over-year increase in operating expenses was due primarily to spending on product and market development initiatives, including expansion of our sales force and the addition of research and development personnel.

On a GAAP basis, other expense totaled $1.8 million in the third quarter of 2010 versus other income of $3.8 million in the third quarter a year ago. On a non-GAAP basis, other income totaled $354,000 versus other income of $504,000 a year ago. Other income on a GAAP basis in the third quarter of 2009 included a $5.2 million fair value gain on an embedded conversion feature within the HeartWare loan. The impact of the embedded conversion feature is excluded on a non-GAAP basis. Other income and expense on a non-GAAP basis is described later in this press release.

The company's GAAP effective tax rate for the third quarter of 2010 was 37.4 percent versus 33.4 percent a year ago. The non-GAAP tax rate, which is described later in this press release, was 35.5 percent in the third quarter of 2010 versus 34.2 percent a year ago. The increase in the GAAP and non-GAAP effective tax rates was due to higher pre-tax income and return to provision adjustments.

Cash and investments at the end of the third quarter of 2010 were $410.1 million versus $376.3 million at the end of the second quarter of 2010 and $331.6 million at the end of fiscal 2009.

GUIDANCE FOR FISCAL 2010 FROM CONTINUING OPERATIONS

The company continues to expect that our full year revenues from continuing operations will be in the range of $380 to $385 million in 2010. GAAP net income per diluted share is expected to be between $0.97 and $1.01 and non-GAAP net income per diluted share is expected to be between $1.19 and $1.23.

CONFERENCE CALL/WEBCAST INFORMATION

Thoratec will hold a conference call to discuss its financial results and operating activities for all interested parties at 1:30 p.m., Pacific Daylight Time, (4:30 p.m., Eastern Daylight Time) today. The teleconference can be accessed by calling (719) 325-4908, passcode 2416731. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available via the Internet at http://www.thoratec.com. A replay of the conference call will be available through Thursday, November 4, via http://www.thoratec.com, or by telephone at (719) 457-0820, passcode 2416731.

GAAP TO NON-GAAP RECONCILIATION

Thoratec management evaluates and makes operating decisions using various measures. These measures are generally based on revenues generated by its products and certain costs of producing those revenues, such as costs of product sales, research and development and selling, general and administrative expenses. We use the following measures, which are not calculated in accordance with Generally Accepted Accounting Principles ("GAAP"): non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP other income and expense,  non-GAAP tax rate, non-GAAP net income, non-GAAP net income per diluted share and non-GAAP shares used to compute diluted net income per share. These are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. These non-GAAP financial measures are calculated by excluding certain GAAP financial items that we believe have less significance to the day-to-day operation of our business.  The company has outlined below the type and scope of these exclusions and the limitations on the use of the non-GAAP financial measures as a result of these exclusions.

Management uses these non-GAAP financial measures for financial and operational decision making, including in the determination of employee annual cash incentive compensation, as a means to evaluate period-to-period comparisons, as well as comparisons to our competitors' operating results.  Management also uses this information internally for forecasting and budgeting, as it believes that the measures are indicative of Thoratec core operating results.  Management also believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company's business operations, provide a greater transparency with respect to key metrics used by management in its decision making, facilitate comparisons of results for current periods and guidance for future periods with our historical operating results, and assist in analyzing future trends.

Non-GAAP net income consists of GAAP net income, excluding, as applicable, the tax effected impact of share-based compensation expense, amortization of purchased intangibles, expenses associated with the retrospective adoption of the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements in accordance with Financial Accounting Standards Board ("FASB") issued Accounting Standards Codification ("ASC") 470-20, Debt, HeartWare transaction costs and unrealized gains on the equity conversion option included in the HeartWare loan agreement.

Non-GAAP net income per diluted share is defined as non-GAAP net income divided by the weighted average number of shares on a fully-diluted basis.  

Non-GAAP shares used to compute diluted net income per share consists of GAAP shares used to compute diluted net income per share adjusted for any inclusions made in conjunction with dilutive impact of Thoratec's convertible debt instruments and any exclusions made in conjunction with the application of the two-class method for calculating net income per share.

Non-GAAP gross profit and gross margin consist of GAAP gross profit and gross margin excluding share-based compensation expense.Non-GAAP operating expenses consist of GAAP operating expenses excluding share-based compensation expense, amortization of purchased intangibles, and HeartWare transaction costs.

Non-GAAP other income and expense consists of GAAP other income and expenses excluding expenses related to the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt and unrealized gains on the equity conversion option included in the HeartWare loan agreement.

Non-GAAP tax rate consists of the GAAP tax rate adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income.

Management believes that it is useful in measuring Thoratec's operations to exclude amortization of intangibles.  These costs are primarily fixed at the time of an acquisition and, unlike other fixed costs that result from ordinary operations, are the result of infrequent and irregular events.

Because of varying valuation methodologies, subjective assumptions and the variety of award types that companies can use, Thoratec management believes that providing non-GAAP financial measures that exclude share-based compensation allows investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods.  The exclusion also enhances investors' ability to review Thoratec's business from the same perspective as Thoratec management, which believes that share-based compensation expense is not directly attributable to the underlying performance of the company's business operations.

Due to the subjective assumptions used to develop non-cash interest expense related to the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt, Thoratec management believes that providing non-GAAP financial measures that exclude such expense allows investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods.  The exclusion also enhances investors' ability to review Thoratec's business from the same perspective as Thoratec management.

To enable investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods, Thoratec has excluded the HeartWare transaction costs as they are non-recurring in nature.

There are a number of limitations related to the use of non-GAAP financial measures.  First, non-GAAP financial measures exclude some costs, namely share-based compensation, that are recurring expenses.  Second, share-based compensation is part of an employee's compensation package and as such may be useful for investors to consider.  Third, the components of costs that we exclude in our non-GAAP financial measures calculations may differ from components that our peer companies exclude when they report their results from operations.

Non-GAAP financial measures should not be considered as a substitute for measures of financial performance in accordance with GAAP. However, these measures may provide additional insight into Thoratec's financial results. Investors and potential investors are strongly encouraged to review the reconciliation of non-GAAP financial measures contained within this press release with their most directly comparable GAAP financial results and not to rely on any single financial measure to evaluate our business.

The reconciliations of the forward looking non-GAAP financial measures to the most directly comparable GAAP financial measures in the tables below include all information reasonably available to Thoratec at the date of this press release.  These tables include adjustments that we can reasonably predict.  Events that could cause the reconciliation to change include acquisitions and divestitures of business, goodwill and other asset impairments and sales of marketable equity securities.

The following table includes the GAAP income statement for continuing operations for the three and nine month periods ending 2010 and 2009:THORATEC CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except for per share data) Three Months Ended Nine Months Ended October 2,
2010October 3,
2009October 2,
2010October 3,
2009Product sales$
90,996$
5,114$
285,366$
98,965Cost of product sales28,62119,97690,77167,027Gross profit62,37545,138194,595131,938Operating expenses:Selling, general and administrative21,10418,28364,01062,625Research and development12,33210,60544,13531,705Amortization of purchased intangible assets2,4462,3597,3267,441Total operating expenses35,88231,247115,471101,771Income from operations26,49313,89179,12430,167Other income and (expense):Interest expense(3,125)(3,261)(9,280)(9,167)Interest income and other1,3627,0604,2619,304Impairment on strategic investment(11)-(2,057)-Income before income taxes24,71917,69072,04830,304Income tax expense (9,239)(5,914)(25,667)(9,472)Net income from continuing operations15,48011,77646,38120,832Net (loss) from discontinued operations (net of tax)(1,183)1(3,697)(1,595)Net Income$
4,297$
,777$
42,684$
9,237Net income (loss) per share - Basic:Continuing operations$0.26$0.21$0.80$0.37Discontinued operations($0.02)$0.00(0.06)($0.03)Net Income$
.24$
.21$
.74$
.34Net income (loss) per share - Diluted:Continuing operations$0.26$0.20$0.78$0.36Discontinued operations($0.02)$0.00($0.06)($0.03)Net Income$
.24$
.20$
.72$
.33Shares used to compute net (loss) income per share (1):Basic58,13856,04557,47355,787Diluted66,61257,36866,21657,135(1) The company adopted the two-class method in calculating net income per share on a GAAP basis, which excludes the weighted average unvested restricted stock awards outstanding of 323,582 and 638,105 for thethree months ended October 2, 2010 and October 3, 2009, respectively, and 386,808 and 724,469 for the nine monthsended October 2, 2010 and October 3, 2010, respectively.The following table reconciles the specific items excluded from GAAP net income from continuing operations in the calculation of non-GAAP net income from continuing operations and diluted net income per share from continuing operations for the periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Net Income from Continuing Operations
(Unaudited)
(in thousands, except for per share data) Three Months Ended Nine Months Ended Net income reconciliationOctober 2,
2010October 3,
2009October 2,
2010October 3,
2009Net income from continuing operations on a GAAP basis$
5,480$
,776$
46,381$
20,832Share-based compensation expense:- Cost of product sales322234947789- Selling, general and administrative1,8581,6096,0745,153- Research and development7915942,6021,992Amortization of purchased intangibles2,4462,3597,3267,441HeartWare transaction costs-984-12,314Impact of ASC 470-202,1291,9456,1685,659Unrealized gain on embedded derivative
instrument on HeartWare loan-(5,240)-(5,240)Income tax effect of non-GAAP income
before tax607(158)434(1,801)Income tax effect of non-GAAP
adjustments(2,820)(832)(8,236)(8,785)Net income from continuing operations on a non-GAAP basis$
20,813$
3,271$
,696$
38,354 Three Months Ended Nine Months Ended Diluted net income from continuing operations per share reconciliationOctober 2,
2010October 3,
2009October 2,
2010October 3,
2009Diluted net income from continuing operations per share on a GAAP basis$
.26$
.20$
.78$
.36Share-based compensation expense:- Cost of product sales--0.020.01- Selling, general and administrative0.020.030.090.09- Research and development0.010.010.040.03Amortization of purchased intangibles0.040.040.110.13HeartWare transaction costs-0.02-0.22Impact of ASC 470-200.030.03-0.10Unrealized gain on embedded derivative
instrument on HeartWare loan-(0.09)-(0.09)Income tax effect of non-GAAP income
before tax0.01-0.01(0.03)Income tax effect of non-GAAP
adjustments(0.05)(0.01)(0.09)(0.15)Convertible debt dilution and two-class
method impact-(0.02)

(1)

(0.01)(0.06)

(1)Diluted net income from continuing operations per share on a non-GAAP basis$
.32$
.21$
.95$
.61 Three Months Ended Nine Months Ended October 2,
2010October 3,
2009October 2,
2010October 3,
2009Shares used to compute diluted net income from continuing operations per share reconciliationShares used in calculation of diluted net income per share --GAAP66,61257,36866,21657,135Convertible debt dilution impact (1)7,2907,290Weighted average unvested
restricted stock awards (2)324638387724Shares used in calculation of diluted net income from continuing operations per share -- Non-GAAP66,93665,29666,60365,149(1) The company's total diluted share count on a GAAP and non-GAAP basis for the three and nine months ended October 2, 2010 included approximately 7.2 million shares and 7.1 million shares, respectively, underlying its  convertible notes as they were dilutive for the respective periods. The company's total diluted share count on a non-GAAP basis for the three and nine months ended October 3, 2009 included approximately 7.3 million shares underlying its convertible notes as they were dilutive for the respective periods (2) The company adopted the two-class method in calculating net income per share on a GAAP basis, which excludes the weighted average unvested restricted stock awards outstanding of 323,582 and 638,105 for the three months ended October 2, 2010 and October 3, 2009, respectively, and 386,808 and 724,469 for the nine months ended October 2, 2010 and October 3, 2010, respectively.The following table reconciles the specific items excluded from GAAP gross profit and gross margin from continuing operations in the calculation of non-GAAP gross profit and gross margin from continuing operations for the periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Gross Profit from Continuing Operations
(Unaudited)
(in thousands) Three Months Ended Nine Months Ended October 2,
2010October 3,
2009October 2,
2010October 3,
2009Gross profit from continuing operations on a GAAP basis

$
2,375

68.5%

$
45,138

69.3%$
94,595

68.2%

$
31,938

66.3%Share-based compensation
expense

322234947789Gross profit from continuing operations on a non-GAAP basis

$
2,697

68.9%

$
45,372

69.7%$
95,542

68.5%

$
32,727

66.7%The following table reconciles the specific items excluded from GAAP operating expenses from continuing operations in the calculation of non-GAAP operating expenses from continuing operations for the periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Operating Expenses from Continuing Operations
(Unaudited)
(in thousands) Three Months Ended Nine Months Ended October 2,
2010October 3,
2009October 2,
2010October 3,
2009 Operating expenses from continuing operations on a GAAP basis $
35,882$
31,247$
5,471$
,771Share-based compensation expense:- Selling, general and administrative(1,858)(1,610)(6,074)(5,153)- Research and development(791)(594)(2,602)(1,992)Amortization of purchased intangibles(2,446)(2,359)(7,326)(7,441)HeartWare transaction costs-(984)-(12,314) Operating expenses from continuing operations on a non-GAAP basis $
30,787$
25,700$
99,469$
74,871The following table reconciles the specific items excluded from GAAP other income and expense from continuing operations in the calculation of non-GAAP other income and expense from continuing operations for the periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Other Income and Expense from Continuing Operations
(Unaudited)
(in thousands) Three Months Ended Nine Months Ended October 2,
2010October 3,
2009October 2,
2010October 3,
2009 Other income (expense) from continuing operations on a GAAP basis $
(1,775)$
3,799$
(7,076)$
37Impact of ASC 470-202,1291,9456,1685,659Unrealized gain on embedded derivative instrument on HeartWare
loan-(5,240)-(5,240) Other income (expense) from continuing operations on a non-GAAP basis $
354$
504$
(908)$
556The following table reconciles the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income from continuing operations to non-GAAP net income from continuing operations:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Tax Expense from Continuing Operations
(Unaudited)
(in thousands) Three Months Ended Nine Months Ended October 2,
2010October 3,
2009October 2,
2010October 3,
2009Tax expense from continuing operations on a GAAP basis

$
(9,239)

37.4%

$
(5,914)

33.4%$
(25,667)

35.6%

$
(9,472)

31.3%Share-based compensation
expense and other

(761)(920)(3,495)(2,546)Amortization of purchased
intangibles

(978)(1,002)(2,931)(2,976)HeartWare transaction costs

-(394)-(4,925)Impact of adoption of ASC
470-20

(851)(768)(2,467)(2,235)Unrealized gain on embedded
derivative instrument on
HeartWare loan

-2,096-2,096Return to provision true-up

373-373-Excess compensation
limitations

5-718-Tax expense from continuing operations on a non-GAAP basis

$
(11,451)

35.5%

$
(6,902)

34.2%$
(33,469)

35.2%

$
(20,058)

34.3%The following table reconciles the guidance on a GAAP and non-GAAP basis from continuing operations for the periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP  Forward-Looking Guidance from Continuing Operations
(Unaudited)
(in thousands, except for per share data)Net income per diluted share reconciliation For the Fiscal Year Ending 2010 FromToNet income per diluted share on a GAAP basis from continuing operations

$
.97$
.01Share-based compensation expense

0.130.13Amortization of purchased intangibles

0.100.10Impact of adoption of ASC 470-20

(0.01)(0.01)Income tax effect of non-GAAP income before tax

--Net income per diluted share on a non-GAAP basis from continuing operations

$
.19$
.23Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS and Thoratec® VAD (Ventricular Assist Device) with more than 15,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. ITC, A-VOX Systems, AVOXimeter, HEMOCHRON, ProTime, ProTime InRhythm and IRMA are registered trademarks of International Technidyne Corporation.

Many of the preceding paragraphs, particularly but not exclusively those addressing guidance for fiscal 2010 financial results or future performance, contain forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "projects," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new products and new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products and related gross margin for such product sales, the ability to improve financial performance, the effects of FDA regulatory requirements, our ability to address issues raised by FDA inspections adequately and on a timely basis without a resulting recall of products or interruption of manufacturing or shipment of products, the effects of healthcare reimbursement and coverage policies, the effects of seasonality on Thoratec product sales, the effects of competition and the effects of any merger, acquisition and divestiture related activities. Forward-looking statements contained in this press release should be considered in light these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K and as may be updated in subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 On Thursday, Feb. 11, 2016, surgeons ... David,s North Austin Medical Center successfully completed the first ... ® Surgical System with Trumpf Medical,s advanced operating ... Lakshman , M.D., colorectal surgeon at the Texas Institute ... Table Motion technology, which seamlessly combines the da Vinci ...
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... -- OMS Supply, a large provider of oral surgery supplies ... recent launching of their new company website. The OMS ... enhance the user experience and enable practitioners to browse ... --> --> Despite the fact that ... in early 2016, they have already made an unprecedented ...
Breaking Medicine Technology:
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., ... have closed for the ISE Southeast Awards 2016. Finalists and winners of the ... ISE® Southeast Executive Forum and Awards Gala on March 15, 2016 at the ...
(Date:2/12/2016)... ... 2016 , ... Every winter, someone is killed, injured or loses a home ... Center, part of the Allegheny Health Network, has partnered with Etna Volunteer Fire ... Need Space” campaign. , “Space Heaters Need Space” aims to bring awareness ...
(Date:2/12/2016)... Arlington, TX (PRWEB) , ... February 12, 2016 , ... ... Worth, and other communities across eastern Texas, is launching a cooperative charity drive with ... and families. , Serving more than 50,000 individuals and families in need, the Tarrant ...
Breaking Medicine News(10 mins):